Update on Drugs and Drug News: June 2012

摘要

The US FDA approved this enzyme replacement therapy in May 2012 for the long-term treatment of adults with a confirmed diagnosis of Type 1 (non-neuropathic) Gaucher disease. It is the first approved plant cell-expressed drug that is derived from a proprietary manufacturing system (ProCellEx?, Protalix BioTherapeutics), using genetically engineered carrot cells. Treatment is administered every other week by a health care professional.